TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Hyzaar Asia HEAALTH (0954A-950)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patient is male or female and = 18 years of age~* Patients with essential hypertension previously treated with antihypertensive medications for at least 4 weeks but did not reach the blood pressure goal~Exclusion Criteria:~* History of any condition, therapy, lab abnormality or other circumstance that might confound the results of the study, or interfere with the patient's participation for the full duration of the study, such that it is not in the best interest of the patient/subject to participate~* Pregnant or breastfeeding, or expecting to conceive within the projected duration of the study~* Previous history of severe essential hypertension~* History of stroke or myocardial infarction (heart attack)~* Evidence of renal or liver disease~* Uncontrolled diabetes mellitus~* Any known bleeding disorder~* Known sensitivity or intolerance to the study medication (losartan or hydrochlorothiazide)~* Other antihypertensive medications or medications that may affect blood pressure

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Losartan/HCTZ

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: GS-5734 to Assess the Antiviral Activity, Longer-Term Clearance of Ebola Virus, and Safety in Male Ebola Survivors With Evidence of Ebola Virus Persistence in Semen

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
* INCLUSION CRITERIA:~Individuals must meet all of the following criteria to be eligible for study participation:~* Men more than or equal to 18 years of age.~* One of two semen samples with Ebola virus RNA detection (defined as a positive PCR for NP or GP using the GeneXpert assay within 42 days prior to randomization).~* Willingness to be available for study evaluations for 6 months.~* Willingness to allow storage of biological samples.~* Willingness to be followed by a Participant Tracker.~* Willingness to refrain from alcohol consumption for study days -7 to 14.~* Willingness to comply with MOH \& CDC guidance on using a condom for sexual activity and at least through week 24 of the study.~EXCLUSION CRITERIA:~Individuals meeting any of the following criteria will be excluded from study participation:~* Estimated glomerular filtration rate less than 60 mL/min/1.73m\^2~* History of significant renal disease~* History of significant liver disease~* Evidence of liver disease on physical exam such as ascites~* Aspartate transaminase (AST) or alanine transaminase (ALT), greater than the upper limit of normal, a prothrombin time 1.1 times greater than the upper limits of normal, normal, or a total bilirubin \> 1.5 times the upper limits of normal(per Division of Acquired Immunodeficiency Syndrome (DAIDS) toxicity tables version 2.0 Nov. 2014).~* Presence of Grade 2 or higher abnormalities for: low hemoglobin, low white blood count (WBC), low platelets, or low or high potassium (per DAIDS toxicity tables version 2.0 Nov. 2014).~* Presence of greater than Grade 2 abnormalities for low or high sodium (per DAIDS toxicity tables version 2.0 Nov. 2014).~* Any condition that, in the opinion of the investigator, would compromise the safety of the study subject or staff, or would prevent proper conduct of the study.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- GS-5734 100mg given intravenously daily for 5 days (Type: ACTIVE_COMPARATOR): Male Ebola survivors with persistent Ebola virus in their semen were given GS-5734 100mg intravenously daily for 5 days
- Normal saline intravenously for 5 days (Type: PLACEBO_COMPARATOR): Male Ebola survivors with persistent Ebola virus in their semen were given normal saline intravenously daily for 5 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Combination CCI-779 (Temsirolimus) and Bortezomib (Velcade) in Relapsed and/or Relapsed/Refractory Multiple Myeloma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* 18 years of age or older~* Must have received prior therapy for their myeloma and have relapsed and/or relapsed/refractory multiple myeloma~* Monoclonal protein in the serum of greater than or equal to 1 gm/dL or monoclonal light chain in the urine protein electrophoresis of greater than or equal to 200mg/24 hours, or measurable light chains by free light chain assay of greater than or equal to 10mg/dl, or measurable plasmacytoma~* ECOG Performance Status 0, 1 or 2~* Laboratory values as outlined in the protocol~Exclusion Criteria:~* Uncontrolled infection~* Cytotoxic chemotherapy less than 2 weeks, or biologic therapy less than 2 weeks, or corticosteroids less than 2 weeks prior to registration. Patients may be receiving chronic corticosteroids if they are being given for disorders other than myeloma.~* Pregnant or nursing women~* Men or women of childbearing potential who are unwilling to employ adequate contraception~* Other concurrent chemotherapy, immunotherapy, radiotherapy, or any ancillary therapy considered investigational within 14 days before enrollment~* Known to be HIV positive~* Myocardial infarction within 6 months prior to enrollment or has NYHA Class III or IV hear failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities~* Hypersensitivity to bortezomib, boron or mannitol~* Serious medical or psychiatric illness likely to interfere with participation in this clinical trial~* Patients who may need or are receiving live vaccines for immunization

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CCI779 and Bortezomib Phase I/II (Type: EXPERIMENTAL): In Phase I part, 15 or 25 mg temsirolimus (CCI-779)and 1·3 or 1·6 mg/m² bortezomib was given once a week.In Phase II, patients received intravenous temsirolimus once a week on days 1, 8, 15, 22, and 29 for a cycle of 35 days, and intravenous bortezomib once a week on days 1, 8, 15, and 22 for a cycle of 35 days, the MTD ascertained in the Phase I part.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Prospective, Randomized Controlled Trial on Perioperative Pregabalin to Reduce Late-onset CRPS After TKA

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. History of osteoarthritis~2. Subjects who can understand and communicate in English.~Exclusion Criteria:~1. Younger than 21 years or older than 80 years.~2. American Society of Anesthesiologists physical status IV.~3. Prior usage of gabapentin (or pregabalin) will not be an exclusionary criterion; however, patients will have been withdrawn from these medications for at least 7 days before surgery.~4. Patients with a history of neuropathic pain conditions.~5. Patients who are currently enrolled in another investigational study.~6. Pre-existing heart conditions~7. Patients on thiazolidinedione class of anti-diabetic medications (eg. rosiglitazone, pioglitazone).~   -

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- 1 Placebo (Type: PLACEBO_COMPARATOR): Half of the patients will receive PO placebo for 14 days
- 2 Pregabalin (Type: EXPERIMENTAL): PO pregabalin 300 mg 2 hours prior to surgery, and 150 mg twice a day for 10 postoperative days. Pregabalin will be tapered to 75 mg twice daily between days 11 to 12 and then to 50 mg twice daily between days 13 to 14 post operatively and then stopped.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Thalamic Deep Brain Stimulation for Spasmodic Dysphonia- DEBUSSY Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Clinically diagnosed isolated laryngeal dystonia (adductor spasmodic dysphonia)~* Able to give informed consent~* Patients who fall into the age range of 18-75 years old~* Patients with inadequate medical and BTX management of spasmodic dysphonia~Exclusion Criteria:~* Dystonia present in other body parts (i.e- eyes, neck, limbs) in addition to larynx~* History of laryngeal denervation surgery for spasmodic dysphonia~* History of intracranial pathology (such as multiple sclerosis, tumors, or aneurysms) that may account for dystonia or essential tremor.~* History or evidence of ongoing psychiatric or neurodegenerative disorders (such as Parkinson's disease, Alzheimer's disease).~* Incompetent adults or those unable to communicate.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- DBS-on (Type: EXPERIMENTAL): Ventral intermediate Nucleus (VIM) Thalamic DBS on~DBS system includes:~* Implantable Pulse Generator (IPG)~* DBS Lead~* DBS Lead Extension Kit
- DBS-off (sham-stimulation) (Type: SHAM_COMPARATOR): Ventral intermediate Nucleus (VIM) Thalamic DBS off~DBS system includes:~* Implantable Pulse Generator (IPG)~* DBS Lead~* DBS Lead Extension Kit

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Letrozole Versus Clomifene Citrate for Ovulation Induction

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age: 18 - 39~2. BMI \< 36~3. Infertility due to anovulation~4. PCOS: At least two of the following diagnostic criteria of:~   1. Oligo/amenorrhoea~  2. Hyperandrogenaemia: biochemical (testosterone ≥2.5 nmol/l or free androgen index (FAI) ≥ 5) or clinical (acne/hirsutism) evidence~  3. USS evidence of PCO (either ≥12 follicles measuring 2-9 mm in diameter, or an ovarian volume of \> 10 ml)~5. No recent (within 6 months) treatment for induction of ovulation~6. Normal semen analysis (WHO 1999)~7. Proven patency of at least one Fallopian tube~Exclusion Criteria:~1. Inability to give informed consent~2. Contraindication to letrozole or clomifene citrate~3. Absence of any inclusion criteria

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 39 Years
- Healthy Volunteers: f

Study Arms:
- Clomiphene citrate (Type: ACTIVE_COMPARATOR): Starting daily dose 50 mg on menstrual cycles days 2 to 6, to be increased to 100 mg daily if there is no response to 50 mg
- Letrozole (Type: ACTIVE_COMPARATOR): Starting daily dose 2.5 mg on menstrual cycles days 2 to 6, to be increased to 5 mg daily if there is no response to 2.5 mg

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study of the Simultaneous Treatment of Upper Facial Lines (Horizontal Forehead Lines, Glabellar Frown Lines and Lateral Canthal Lines) in Subjects With Moderate to Severe Upper Facial Lines

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Outpatients (male or female) 18 years of age or older.~* Horizontal forehead lines (HFL), glabellar frown lines (GFL), and symmetrical lateral canthal lines (LCL) of moderate to severe intensity at maximum contraction as assessed by the investigator and subject according to Merz Aesthetics Scales (MAS).~Exclusion Criteria:~* Previous treatment with botulinum neurotoxin (BoNT) of any serotype in the face within the last 12 months before injection.~* Any facial cosmetic procedure within the last 12 months before baseline injection.~* Previous treatment with any biodegradable filler in the face within the last 12 months before injection.~* Any previous insertion of permanent material in the face (regardless of the time between previous treatment and this study).~* Any medical condition that may put the subject at increased risk with exposure to NT201.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Main Period: Placebo (Group P) (Type: PLACEBO_COMPARATOR): Subjects will receive placebo injection in all three UFL (GFL, HFL and LCL) on Day 1 of main period.
- Main Period: NT 201 (Group U) (Type: EXPERIMENTAL): Subjects will receive a total of 64 Units (U) of NT 201: 20 U of NT 201 injection both in the GFL area and in the HFL area, and 24 U of NT 201 injection in the LCL area (12 U per side) on Day 1 of main period.
- Main Period: NT 201 and Placebo (Group G and H) (Type: EXPERIMENTAL): Subjects will receive a total of 40 U of NT 201: 20 U of NT 201 injection both in the GFL and HFL area, and placebo injection in the LCL area on Day 1 of main period.
- OLEX: NT 201 (Main Period: Group P) (Type: EXPERIMENTAL): Subjects will receive a total of 64 U of NT 201: 20 U of NT 201 injection both in the GFL and in the HFL area, and 24 U of NT 201 injection in the LCL area (12 U per side) on Day 1 (Visit 8) and Visit 13 of OLEX period.
- OLEX: NT 201 (Main Period: Group U) (Type: EXPERIMENTAL): Subjects will receive a total of 64 U of NT 201: 20 U of NT 201 injection both in the GFL and in the HFL area, and 24 U of NT 201 injection in the LCL area (12 U per side) on Day 1 (Visit 8) and Visit 13 of OLEX period.
- OLEX: NT 201 (Main Period: Group G and H) (Type: EXPERIMENTAL): Subjects will receive a total of 64 U of NT 201: 20 U of NT 201 injection both in the GFL and in the HFL area, and 24 U of NT 201 injection in the LCL area (12 U per side) on Day 1 (Visit 8) and Visit 13 of OLEX period.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Zonisamide to Prevent Olanzapine-Associated Weight Gain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Criteria for entering this study will include all of the following:~1. Subjects must be 18 years of age or older.~2. Subjects must have schizophrenia, schizoaffective disorder, schizophreniform disorder, delusional disorder, psychotic disorder NOS, or bipolar I, II, or NOS disorder as defined by DSM-IV-TR criteria.~3. Subjects must have a BMI \> 22.~4. Subjects must sign the Informed Consent Document after the nature of the trial has been fully explained.~5. If female, subjects must be: postmenopausal, surgically incapable of childbearing, or practicing medically acceptable effective method(s) of contraception (e.g., hormonal methods, intrauterine device) for at least one month prior to study entry and throughout the study.~6. If exposed to olanzapine in the past, subjects must be free of olanzapine for \> 3 months prior to randomization to study medication.~Exclusion Criteria:~Criteria for exclusion from this study will be any of the following:~1. Subjects with clinically significant suicidal or homicidal ideation.~2. Subjects with a current DSM-IV Axis I diagnosis of delirium, dementia, amnesia, or other cognitive disorders; a psychotic or mood disorder secondary to substance use or a general medical disorder; or a DSM-IV diagnosis of a substance use disorder within the past six months.~3. Cardiovascular, endocrine, neurologic, or hematologic disease as determined by the clinical judgment of the clinical investigator. Subjects with hypo- or hyperthyroidism unless stabilized on thyroid replacement \> 3 months.~4. Subjects who are allergic to or who have demonstrated hypersensitivity to or significant adverse event from olanzapine.~5. Subjects who are allergic to or who have demonstrated hypersensitivity to zonisamide.~6. Women who are pregnant or nursing.~7. Subjects who have received an experimental drug or used an experimental device within 30 days.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sugar pill (Type: EXPERIMENTAL): olanzapine and placebo (sugar pill)
- Zonisamide (Type: EXPERIMENTAL): olanzapine and zonisamide (active drug)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Assess The Efficacy and Safety of a PARP Inhibitor For The Treatment of BRCA-positive Advanced Breast Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Advanced breast cancer with positive BRCA1 or BRCA2 status~* Failed at least one prior chemotherapy~* In investigators opinion, no curative standard therapy exists~* Measurable disease~Exclusion Criteria:~* Brain metastases~* Less than 28 days since last treatment used to treat the disease~* Considered a poor medical risk due to a serious uncontrolled disorder

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 130 Years
- Healthy Volunteers: f

Study Arms:
- Olaparib 100 mg (Type: EXPERIMENTAL): Participants will receive two 50 mg capsules in the morning and two 50 mg capsules in the evening in 28-days cycle until confirmed disease progression, continuous treatment interruption, unacceptable toxicity or any other discontinuation criterion is met.
- Olaparib 400 mg (Type: EXPERIMENTAL): Participants will receive eight 50 mg capsules in the morning and eight 50 mg capsules in the evening in 28-days cycle until confirmed disease progression, continuous treatment interruption, unacceptable toxicity or any other discontinuation criterion is met.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Venous Thromboembolic Prophylaxis After Trauma: Three Times a Day Unfractionated Heparin Versus Twice a Day Enoxaparin

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Admitted to Scripps Mercy Trauma Service~* ≥18 Years old~* Stratified to either Significant or Highest risk of VTE by ACCP guidelines~Exclusion Criteria:~* Estimated Injury Severity Score (ISS) ≤9~* Likely to be discharged before hospital day 7~* Systemic coagulopathy defined with an International Normalized Ratio (INR) of ≥1.2~* Body Mass Index (BMI) \>40~* Likely to Survive for \<7 Days~* Pregnancy~* Evidence of renal insufficiency (Cr ≥1.3)~* Delayed transfer to this facility (\>24 hrs)~* Prisoners

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 5000 Units unfractionated Heparin Q 8 hr (Type: EXPERIMENTAL): Low Dose Unfractionated Heparin (5000 Units) given every eight hours until primary or secondary outcome measure reached, discharge, or \>30 days on trauma service.
- 30mg enoxaparin Q12 hr (Type: ACTIVE_COMPARATOR): Randomly assigned trauma patients to receive Low Molecular Weight Heparin (30mg enoxaparin) given subcutaneously every twelve hours until primary or secondary outcome measure reached, discharge, or \>30 days on trauma service.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Rivaroxaban With Diosmin in Long-term Treatment of Deep Vein Thrombosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age over 18 years~* The first episode of femoro-popliteal deep vein thrombosis (DVT)~* Verification of DVT by duplex ultrasound~* Informed consent signed~Exclusion Criteria:~* Suspicion of pulmonary embolism (PE)~* Verified PE~* Bilateral DVT~* Contraindications for rivaroxaban (in accordance with the official instructions)~* Contraindications for diosmin (in accordance with the official instructions)~* Active cancer~* Verified severe thrombophilia (antiphospholipid antibodies, deficiency of proteins C, S, antithrombin 3)~* Use of other anticoagulants for more than 7 days from the DVT verification~* Impossibility of using compression stocking after 3 days from DVT verification~* Performed surgical intervention on the superficial or deep veins of the lower extremities (thrombolysis, thrombectomy, vein ligation, implantation of the inferior cava filter)~* Continuous use of other drugs that affect the hemostasis system (except for acetylsalicylic acid in a dose of not more than 100 mg).~* Low compliance

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Experimental: Rivaroxaban + Diosmin + Stockings (Type: EXPERIMENTAL): treatment of deep vein thrombosis with anticoagulation (rivaroxaban), elastic compression stockings and additional prescription of diosmin
- Control: Rivaroxaban + Stockings only (Type: ACTIVE_COMPARATOR): standard treatment of deep vein thrombosis with anticoagulation (rivaroxaban) and elastic compression stockings

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete